NEW PROCEDURE FOR DETERMING

BIOLOGICAL BIOPSY

SPECIFIC ANTIGENES IN IMMUNE CELLS

EDIM technology

  • EDIM technology

    NEW “BIOLOGICAL BIOPSY” FOR DETERMINING SPECIFIC ANTIGENES IN IMMUNE CELLS

    • High specificity
    • High sensitivity
    • Diverse areas of application in oncology
    • Completely automatic measurment and evaluation
  • Principle

    EDIM TECHNOLOGY EXAMINES MONOCYTES AND MACROPHAGES

    For this purpose, CD14 and CD16 surface antibodies are used, which bind specifically to the surface of the cells. The cells are then permeabilised briefly to induce further antibodies to enter the cells.

Projects

CANCER SCREENING:

Development of a universal cancer test based on the EDIM technology using the markers TKTL1 and Apo10

Partner:

  • Prof. Dr. med. Salah-Eddin Al-Batran | Medical Director Hospital Northwest Frankfurt
  • PD Dr. med. G.-André Banat, MBA | Chief physician of the Clinic for Internal Medicine at the Hochwaldkrankenhaus Bad Nauheim 

PROSTATE CANCER AFTER-CARE:

Development of a PSMA test for the selection of suitable patients for new therapeutic approaches for metastatic prostate cancer using radioactively labelled PSMA ligands

Partner: Prof. Dr. med. Richard Baum | Chief physician Clinic for Molecular Radiotherapy Central Clinic Bad Berka

CHECKPOINT INHIBITORS:

Detection of PD-L1 and PD-L2 on tumour cells

Partner: Dr. Wilfried Stücker | IOZK (IOZK Immunological Oncology Centre Cologne)

NEUROBLASTOMA:

Verification of a neuroblastoma and the GD2 target structure for modern immunotherapies

Partner: Prof. Dr. med. Rupert Handgretinger  | Medical Director General Paediatrics, Haematology / Oncology Children’s hospital Tübingen

NEWS

About Zyagnum

OUR CLAIM
ZYAGNUM AG IS AN INNOVATIVE TECHNOLOGY COMPANY WITH VISION AND GLOBAL DEMAND.
  • Universal cancer test
  • Further development of the test procedure
© Copyright 2017 - Zyagnum AG